Back to Search
Start Over
Prognosis impact of posttreatment pelvic MRI in patients treated for stage IB2-IIB cervical cancer with chemoradiation therapy
- Source :
- EJSO-European Journal of Surgical Oncology, EJSO-European Journal of Surgical Oncology, 2021, 47 (5), pp.1103-1110. ⟨10.1016/j.ejso.2020.10.009⟩, EJSO-European Journal of Surgical Oncology, WB Saunders, 2021, 47 (5), pp.1103-1110. ⟨10.1016/j.ejso.2020.10.009⟩
- Publication Year :
- 2021
- Publisher :
- HAL CCSD, 2021.
-
Abstract
- International audience; OBJECTIVES: To evaluate the performances of systematic posttreatment pelvic magnetic resonance imaging (PPMRI) in predicting prognosis of patients treated with chemoradiation therapy (CRT) for locally advanced cervical cancer (LACC). MATERIALS AND METHODS: Multi-institutional data from 216 patients presenting FIGO IB2-IIB cervical cancer for which PPMRI was performed following CRT were retrospectively reviewed. Incomplete response was defined as the identification of persistent lesion on PPMRI. Primary endpoints were patients’ 5-year recurrence free (RFS) and overall (OS) survivals. Secondary endpoint was the identification of residual histologic disease on hysterectomy specimens when completion surgery was performed. RESULTS: PPMRI identified an incomplete response in 102 (47.2%) cases. A 70% or more reduction in tumor size on PPMRI was identified as the best predictive cut-off for recurrence (37.7% sensitivity and 78.7% specificity) and death (50% sensitivity and 77.9% specificity) with significant impact on those risks (HRa: 0.42; 95%CI: 0.23-0.77 and HRa: 0.18; 95%CI: 0.06-0.50, respectively). Completion hysterectomy was performed in 117 (54.4%) cases, with histologic residual disease in 55 (47.4%). PPMRI demonstrated 74.5% sensitivity and 50.8% specificity in predicting residual disease. Although survival of patients with complete response at PPMRI was not impacted by completion hysterectomy, it significantly increased 5-year RFS and OS of those with incomplete response: 38.7% vs. 65.3% (p
- Subjects :
- medicine.medical_specialty
Survival
[SDV.MHEP.CHI] Life Sciences [q-bio]/Human health and pathology/Surgery
medicine.medical_treatment
Uterine Cervical Neoplasms
[SDV.CAN]Life Sciences [q-bio]/Cancer
Disease
[SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/Surgery
Hysterectomy
030218 nuclear medicine & medical imaging
Lesion
03 medical and health sciences
0302 clinical medicine
[SDV.CAN] Life Sciences [q-bio]/Cancer
Predictive Value of Tests
Recurrence
medicine
Humans
In patient
Pelvic MRI
Stage (cooking)
Neoplasm Staging
Retrospective Studies
Cervical cancer
medicine.diagnostic_test
business.industry
Magnetic resonance imaging
Chemoradiotherapy
General Medicine
Middle Aged
medicine.disease
Prognosis
Magnetic Resonance Imaging
3. Good health
Survival Rate
Oncology
Chemoradiation
030220 oncology & carcinogenesis
Female
Surgery
Radiology
Neoplasm Recurrence, Local
medicine.symptom
business
Subjects
Details
- Language :
- English
- ISSN :
- 07487983
- Database :
- OpenAIRE
- Journal :
- EJSO-European Journal of Surgical Oncology, EJSO-European Journal of Surgical Oncology, 2021, 47 (5), pp.1103-1110. ⟨10.1016/j.ejso.2020.10.009⟩, EJSO-European Journal of Surgical Oncology, WB Saunders, 2021, 47 (5), pp.1103-1110. ⟨10.1016/j.ejso.2020.10.009⟩
- Accession number :
- edsair.doi.dedup.....7d482481b900e1f25f112da918f9e66b
- Full Text :
- https://doi.org/10.1016/j.ejso.2020.10.009⟩